OBJECTIVES: Cervical cancer is the third leading cause of cancer-related mortality in females. One of the most successful therapeutic modalities to date is suppressing Vascular endothelial growth factor (VEGF) mediated angiogenesis. Bevacizumab is a monoclonal antibody that targets VEGF-A. The outcomes and safety considerations for patients with cervical cancer treated with Bevacizumab in combination with platinum-based chemotherapy have been explored in several studies. The objective of this meta-analysis was to assess the impact of Bevacizumab on overall survival (OS) in patients with cervical cancer.

METHODS: Following PRISMA guidelines, a comprehensive literature search on PubMed and Google Scholar was performed to identify relevant studies. Keywords used in searching were: Bevacizumab, Cervical Cancer, Efficacy, Metastasis, Monoclonal antibody, Meta-analysis. The outcome of interest was OS. Statistical analysis computed hazard ratios (HR) with 95% confidence intervals (CIs). The I² statistic test was used to examine statistical heterogeneity. The study also involved a subgroup analysis by stage of cervical cancer.

RESULTS: The pooled analysis revealed that Bevacizumab-based therapy significantly improved OS with HR 0.63 (95% CI: 0.45-0.89; p<0.01; I2 = 41%) in cervical cancer patients.><0.01; I²=41%). Subgroup analysis by stage of cervical cancer demonstrated better efficacy of Bevacizumab in metastatic stage IVB cervical cancer patients revealed by HR for OS (0.57, 95% CI: 0.46-0.73; p<0.01).

CONCLUSIONS: Bevacizumab exhibited a significant increase in OS, underscoring the efficacy of anti-angiogenesis therapy in cervical cancer. Robust statistical analyses supported Bevacizumab's potential as a meaningful therapeutic intervention in cervical cancer especially in stage IVB metastatic cervical cancer patients.